A generic manufacturer whose market entry strategy depends on patent expiration alone may still be blocked by an exclusivity period that runs years past that date
Originally developed as a treatment for Type 2 diabetes, Semaglutide has been FDA-approved for weight loss in individuals with obesity
In comparison, Ozempic primarily aims to improve blood sugar control in people with type 2 diabetes and is used at lower doses (0.5mg or 1.0mg once weekly)
It works by imitating a hormone that controls hunger and blood sugar levels, helping to reduce hunger and increase feelings of fullness
An approved antidiabetic treatment due to its hypoglycemic effects, it is of further clinical interest as an appetite suppressant and weight loss agent, indicated for chronic weight management in non-diabetic obese and overweight patients
Long-Acting Formulation: Some versions of semaglutide are designed to provide sustained effects with weekly injections, reducing the need for frequent dosing and making it more convenient for patients.
